# Erlotinib Study for Myelodysplastic Syndrome (MDS)

> **NCT00977548** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 39 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00977548
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2013-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977548, "Erlotinib Study for Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00977548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*